-
The competing risk approach for prediction of preeclampsia.
Wright D, Wright A, Nicolaides KH.
Am J Obstet Gynecol 2020;223:12-23.e7. pdf -
Screening for trisomy at 11-13 weeks' gestation: use of pregnancy-associated plasma protein-A, placental growth factor or both.
Mazer Zumaeta A, Wright A, Syngelaki A, Maritsa VA, Bardani E, Nicolaides KH.
Ultrasound Obstet Gynecol 2020;56:408-415. pdf -
Screening for pre-eclampsia at 11-13 weeks' gestation: use of pregnancy-associated plasma protein-A, placental growth factor or both.
Mazer Zumaeta A, Wright A, Syngelaki A, Maritsa VA, Da Silva AB, Nicolaides KH.
Ultrasound Obstet Gynecol 2020;56:400-407. pdf -
Mini-combined test compared with NICE guidelines for early risk-assessment for pre-eclampsia: the SPREE diagnostic accuracy study.
Poon LC, Wright D, Thornton S, Akolekar R, Brocklehurst P, Nicolaides KH.
Southampton (UK): NIHR Journals Library 2020 pdf -
Impact of new definitions of pre-eclampsia on incidence and performance of first-trimester screening.
Khan N, Andrade W, De Castro H, Wright A, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2020;55:50-57. pdf -
Establishing a Differential Marker Profile for Pregnancy Complications Near Delivery.
Sharabi-Nov A, Kumar K, Fabjan Vodušek V, Premru Sršen T, Tul N, Fabjan T, Meiri H, Nicolaides KH, Osredkar J.
Fetal Diagn Ther 2020;47:471-484. pdf -
Competing-risks model for prediction of small-for-gestational-age neonates from maternal characteristics, serum PAPP-A and PlGF at 11-13 weeks' gestation.
Papastefanou I, Wright D, Lolos M, Anampousi K, Mamalis M, Nicolaides KH.
Ultrasound Obstet Gynecol 2021;57:392-400 pdf -
Study protocol for the randomised controlled trial: combined multimarker screening and randomised patient treatment with ASpirin for evidence-based PREeclampsia prevention (ASPRE)
O'Gorman N, Wright D, Rolnik DL, Nicolaides KH, Poon LC.
BMJ Open 2016;6:e011801. pdf -
Prediction of stillbirth from biochemical and biophysical markers at 11-13 weeks.
Mastrodima S, Akolekar R, Yerlikaya G, Tzelepis T, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;48:613-7. pdf -
Contingent screening for preterm pre-eclampsia.
Wright D, Gallo DM, Gil Pugliese S, Casanova C, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:554-9. pdf -
Prediction of large-for-gestational-age neonates: screening by maternal factors and biomarkers in the three trimesters of pregnancy.
Frick AP, Syngelaki A, Zheng M, Poon LC, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:332-9. pdf -
First trimester prediction of HELLP syndrome.
Oliveira N, Poon LC, Nicolaides KH, Baschat AA.
Prenat Diagn 2016;36:29-33. pdf -
Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks gestation.
O'Gorman N, Wright D, Syngelaki A, Akolekar R, Wright A, Poon LC, Nicolaides KH.
Am J Obstet Gynecol 2016;214:103.e1-103.e12 . pdf -
Contingent Screening for Small by Weight for Gestational Age Neonates.
Frick AP, Nicolaides KH, Poon LC.
Pediatr Endocrinol Rev 2016;13:568-73. -
First-trimester biochemical markers of placentation in screening for gestational diabetes mellitus.
Syngelaki A, Kotecha R, Pastides A, Wright A, Nicolaides KH.
Metabolism 2015;64:1485-9. pdf -
A model for a new pyramid of prenatal care based on the 11 to 13 weeks' assessment.
Nicolaides KH.
Prenat Diagn 2011;31:3-6. -
Turning the pyramid of prenatal care.
Nicolaides KH.
Fetal Diagn Ther 2011;29:183-96.